Oral DHA supplementation in ΔF508 homozygous cystic fibrosis patients

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 78, Issue 2, 2008, Pages 109-115

  Van Biervliet, S ^a   Devos, M ^a   Delhaye, T ^a   Van Biervliet, J P ^a   Robberecht, E ^a   Christophe, A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5,8,11 ICOSATRIENOIC ACID; ALPHA TOCOPHEROL; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN; LIVER ENZYME; OMEGA 6 FATTY ACID; PHOSPHOLIPID; SUNFLOWER OIL;

ADOLESCENT; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LIPID COMPOSITION; LUNG FUNCTION; MALE; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SUPPLEMENTATION; VITAMIN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; FATTY ACIDS; HUMANS; INFANT; MALE; MIDDLE AGED; PHOSPHOLIPIDS; PLACEBOS; POINT MUTATION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

ALGAE; HELIANTHUS;

EID: 39849100408     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2007.12.005     Document Type: Article

References (39)

1. Welsh M.J., and Smith A.E. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73 (1993) 1251-1254
2. Roulet M., Frascardo P., and Pilet M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur. J. Pediatr. 156 (1997) 952-956
3. Farrell P.M., Mischler E.H., Engle M.J., Brown J., and Lau S.M. Fatty acid abnormalities in cystic fibrosis. Pediatr. Res. 19 (1985) 104-109
4. Robinson P.G. Essential fatty acids in cystic fibrosis. Lancet 8 (1975) 919
5. Rogiers V., Dab I., Crokaert R., and Vis H.L. Long chain non-esterified fatty acid pattern in plasma of cystic fibrosis patients and their parents. Pediatr. Res. 14 (1980) 1088-1091
6. Dodge J.A., Salter D.G., and Yassa J.G. Essential fatty acid deficiency due to artificial diet in cystic fibrosis. Br. Med. J. 11 (1975) 192-193
7. Gibson R.A., Teubner J.K., Haines K., Cooper D.M., and Davidson G.P. Relationships between pulmonary function and plasma fatty acid levels in cystic fibrosis patients. J. Pediatr. Gastroenterol. Nutr. 5 (1986) 408-415
8. Christophe A., and Robberecht E. Current knowledge on fatty acids in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 55 (1996) 129-138
9. Freedman S.D., Blanco P.G., Zaman M.M., Shea J.C., Ollero M., Hopper I.K., et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 350 (2004) 560-569
10. Strandvik B., Gronowitz E., Enlund F., Martinsson T., and Wahlstörm J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J. Ped. 139 (2001) 650-655
11. Rogiers V., Dab I., Michotte Y., Vercruysse A., Crockaert R., and Vis H.L. Abnormal fatty acid turnover in the phospholipids of the red blood cell membranes of cystic fibrosis patients (in vitro study). Pediatr. Res. 18 (1984) 704-709
12. Carlstedt-Duke J., Bronnegard M., and Strandvik B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc. Natl. Acad. Sci. USA 83 (1986) 9202-9206
13. Levistre R., Lemnaouar M., Rybkine T., Bereziat G., and Masliah J. Increase of bradykinin stimulated arachidonic acid release in a delta-F508 cystic fibrosis epithelial cell line. Biochim. Biophys. Acta. 1181 (1993) 233-239
14. Van Biervliet S., Van Billemont G., Van Biervliet J.P., Declercq D., Robberecht E., and Christophe A. Relation between fatty acid composition and clinical status or genotype in cystic fibrosis patients [Abstract]. J. Cyst. Fibros. 6 (2007) S59
15. Freedman S.D., Katz M.H., Parker E.M., Laposata M., Urman M.Y., and Alvarez J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in CFTR-/-mice. Proc. Natd. Aceed. Sci. 96 (1999) 13995-14000
16. Konstan M.W., Byard P.J., Hoppel C.L., and Davis P.B. Effect of high dose ibuprofen in patients with cystic fibrosis. N. Engl. J. Med. 331 (1995) 848-854
17. Oermann C.M. Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future. Curr. Opin. Invest. Drugs. 7 (2001) 900-906
18. Beharry S., Ackerley C., Corey M., Kent G., Heng Y.M., Christensen H., et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. AJP Gastrointest. Liver Physiol. 292 (2007) G839-G848
19. Jumpsen J.A., Brown N.E., Thomson A.B.R., et al. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J. Cyst. Fibros. 5 (2006) 77-84
20. Lloyd-Still J., Powers C.A., Hoffman D.R., Boyd-Trull K., Lester L.A., Benisek D.C., et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 22 (2006) 36-46
21. Williams S.G., Evanson J.E., Barrett N., Hodson M.E., Boultbee J.E., and Westaby D. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J. Hepatol. 22 (1995) 513-521
22. Folch-Pi J., Lees M., and Stanly G.S.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226 (1957) 497-509
23. Christophe A., and Matthijs F. New method for the determination of the fatty acid pattern of serum lipid classes. Clin. Chim. Acta. 16 (1967) 39-43
24. Muskiet F.A.J., Van Doormaal J.J., Mastini I.A., Wolters B.G., and Van der Slik W. Capillary gas chromatography profiling of total long-chain fatty acids and cholesterol in biological materials. J. Chromatogr. 278 (1983) 231-244
25. Christophe A., and Robberecht E. Directed modification instead of normalization of fatty acid patterns in cystic fibrosis: an emerging concept. Curr. Opin. Nutr. Metab. Care 4 (2001) 111-113
26. Christophe A., Robberecht E., Franckx H., De Baets F., and van de Pas M. Effect of administration of gamma-linolenic acid on the fatty acid composition of serum phospholipids and cholesteryl esters in patients with cystic fibrosis. Ann. Nutr. Metab. 38 (1994) 40-47
27. Keicher U., Koletzko B., and Reinhardt D. Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis. Eur. J. Clin. Invest. 25 (1995) 915-919
28. Lawrence R., and Sorell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet 342 (1993) 465-469
29. Kurlandsky L.E., Bennink M.R., Webb P.M., Ulrich P.J., and Baer L.J. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr. Pulmonol 18 (1994) 211-217
30. Panchaud A., Sauty A., Kernen Y., et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover, placebo-controlled trial. Clin. Nutr. 3 (2006) 418-427
31. De Vizia B., Raia V., Spano C., Pavlidis C., Coruzzo A., and Alessio M. Effect of an 8-month treatment with ω-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J. Parenter. Ent. Nutr. 27 (2003) 52-57
32. Dombrowsky H., Clark G.T., Rau G.A., Bernhard W., and Postle A.D. Molecular species compositions of lung and pancreas phospholipids in the CFTRtm1HGU/tm1HGU cystic fibrosis mouse. Ped. Res. 53 (2003) 447-454
33. Werner A., Bongers M.E., Bijvelds M.J., de Jonghe H.R., and Verkade H.J. No indications for altered essential fatty acid metabolism in two murine models for cystic fibrosis. J. Lipid. Res. 45 (2004) 2277-2286
34. Holman R.T. The ratio of trienoic: tetraenoic acids in tissue lipids as a measure of essential fatty acid requirement. J. Nutr. 70 (1960) 405-410
35. Conquer J.A., and Holub B.J. Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores. Lipids 32 (1997) 341-345
36. Chapkin R.S., Hong M.Y., Fan Y.Y., Davidson L.A., Sanders L.M., Henderson C.E., et al. Dietary n-3 PUFA alter colonocyte mitochondrial membrane composition and function. Lipids 37 (2002) 193-199
37. Lands W.E., Libelt B., Morris A., Kramer N.C., Prewitt T.E., Bowen P., Schmeisser D., Davidson M.H., and Burns J.H. Maintenance of lower proportions of (n-6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n-3) fatty acids. Biochim. Biophys. Acta 1180 (1992) 147-162
38. Strandvik B. Fatty acid metabolism in cystic fibrosis. N. Engl. J. Med. 5 (2004) 605-607
39. McKarney C., Everard M., and N'Diaye T. Omega-3 fatty acids (from fish oils) for cystic fibrosis (Review). Cochrane Lib. 4 (2007) 1-14